glp-1 agonist alcohol receptor agonists show promise in treating substance use disorders GLP‐1 Receptor Agonists for Treating

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited

At Internal Medicine and Family Practice, Dr

02/16/2026 Electronic publication Footnotes Conflict of interest: TF has served on advisory boards for Peptron, Abbvie, Eli Lilly, Bluerock, Bayer, and Bial

Key Facts A record high 11% of Americans are taking a GLP-1 medication for weight loss, according to Gallup , up 3% from 2024

In comparison, antagonism of the GIPR did not alter the actions of 3 nmol kg 1 of tirzepatide to reduce glycemia or influence the effect of the GLP-1R antagonist on glucose tolerance (Fig

This is what has caused some people to view it as not only the next-generation anti-obesity drug but also as one to follow